Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

What is the best way to manage patients treated with gefitinib for non-small-cell lung cancer?

Nature Clinical Practice Oncology volume 2, pages 290–291 (2005)Cite this article

boxed-textShah NT et al. (2005) Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 23: 165–174

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Green MR (2004) Targeting targeted therapy. N Engl J Med 350: 2191–2193

    Article  CAS  Google Scholar 

  2. Lynch TJ et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139

    Article  CAS  Google Scholar 

  3. Paez JG et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497–1500

    Article  CAS  Google Scholar 

  4. Shigematsu H et al. (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339–346

    Article  CAS  Google Scholar 

  5. Thatcher N et al. (2005) Results of a Phase III placebo-controlled study (ISEL) of gefitinib (IRESSA) plus best supportive care (BSC) in patients with advanced non-small-cell lung cancer (NSCLC) who had received 1 or 2 prior chemotherapy regimens [abstract #LB-6]. ISEL Investigators. AACR 96th Annual Meeting

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Assistant Professor of Department of Pulmonary Medicine, Pulmonary Medicine and Cancer Biology, University of Texas M.D. Anderson Cancer Center,

    Amir Onn

  2. Medical Oncology and Cancer Biology,

    Roy S Herbst

  3. Lung Cancer Section, University of Texas M.D. Anderson Cancer Center,

    Roy S Herbst

Authors
  1. Amir Onn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roy S Herbst
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amir Onn.

Ethics declarations

Competing interests

Amir Onn received honoraria from AstraZeneca. Roy S Herbst is a consultant and has received research funds from AstraZeneca.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Onn, A., Herbst, R. What is the best way to manage patients treated with gefitinib for non-small-cell lung cancer?. Nat Rev Clin Oncol 2, 290–291 (2005). https://doi.org/10.1038/ncponc0191

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0191

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing